Literature DB >> 33189799

KALRN: A central regulator of synaptic function and synaptopathies.

Euan Parnell1, Lauren P Shapiro1, Roos A Voorn1, Marc P Forrest1, Hiba A Jalloul1, Daniel D Loizzo1, Peter Penzes2.   

Abstract

The synaptic regulator, kalirin, plays a key role in synaptic plasticity and formation of dendritic arbors and spines. Dysregulation of the KALRN gene has been linked to various neurological disorders, including autism spectrum disorder, Alzheimer's disease, schizophrenia, addiction and intellectual disabilities. Both genetic and molecular studies highlight the importance of normal KALRN expression for healthy neurodevelopment and function. This review aims to give an in-depth analysis of the structure and molecular mechanisms of kalirin function, particularly within the brain. These data are correlated to genetic evidence of patient mutations within KALRN and animal models of Kalrn that together give insight into the manner in which this gene may be involved in neurodevelopment and the etiology of disease. The emerging links to human disease from post-mortem, genome wide association (GWAS) and exome sequencing studies are examined to highlight the disease relevance of kalirin, particularly in neurodevelopmental diseases. Finally, we will discuss efforts to pharmacologically regulate kalirin protein activity and the implications of such endeavors for the treatment of human disease. As multiple disease states arise from deregulated synapse formation and altered KALRN expression and function, therapeutics may be developed to provide control over KALRN activity and thus synapse dysregulation. As such, a detailed understanding of how kalirin regulates neuronal development, and the manner in which kalirin dysfunction promotes neurological disease, may support KALRN as a valuable therapeutic avenue for future pharmacological intervention.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Alzheimer’s disease; Autism spectrum disorder; Dendritic spine; Developmental delay; KALRN; Kalirin; Neurodegeneration; Neurodevelopment; Schizophrenia; Synaptic plasticity

Mesh:

Substances:

Year:  2020        PMID: 33189799      PMCID: PMC7803032          DOI: 10.1016/j.gene.2020.145306

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  128 in total

1.  Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies.

Authors:  Borislav Dejanovic; Melanie A Huntley; Ann De Mazière; William J Meilandt; Tiffany Wu; Karpagam Srinivasan; Zhiyu Jiang; Vineela Gandham; Brad A Friedman; Hai Ngu; Oded Foreman; Richard A D Carano; Ben Chih; Judith Klumperman; Corey Bakalarski; Jesse E Hanson; Morgan Sheng
Journal:  Neuron       Date:  2018-11-01       Impact factor: 17.173

2.  Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling.

Authors:  Kelly A Jones; Deepak P Srivastava; John A Allen; Ryan T Strachan; Bryan L Roth; Peter Penzes
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-04       Impact factor: 11.205

3.  The Kalirin Gene rs9289231 Polymorphism as a Novel Predisposing Marker for Coronary Artery Disease.

Authors:  Mohammadali Boroumand; Shayan Ziaee; Nosratollah Zarghami; Maryam Sotudeh Anvari; Sara Cheraghi; Seyed Hesameddin Abbasi; Arash Jalali; Leila Pourgholi
Journal:  Lab Med       Date:  2014

4.  Prevalence of autism spectrum disorders in a total population sample.

Authors:  Young Shin Kim; Bennett L Leventhal; Yun-Joo Koh; Eric Fombonne; Eugene Laska; Eun-Chung Lim; Keun-Ah Cheon; Soo-Jeong Kim; Young-Key Kim; Hyunkyung Lee; Dong-Ho Song; Roy Richard Grinker
Journal:  Am J Psychiatry       Date:  2011-05-09       Impact factor: 18.112

5.  Duet is a novel serine/threonine kinase with Dbl-Homology (DH) and Pleckstrin-Homology (PH) domains.

Authors:  T Kawai; H Sanjo; S Akira
Journal:  Gene       Date:  1999-02-18       Impact factor: 3.688

6.  Kalirin inhibition of inducible nitric-oxide synthase.

Authors:  E A Ratovitski; M R Alam; R A Quick; A McMillan; C Bao; C Kozlovsky; T A Hand; R C Johnson; R E Mains; B A Eipper; C J Lowenstein
Journal:  J Biol Chem       Date:  1999-01-08       Impact factor: 5.157

Review 7.  SH3 domains: complexity in moderation.

Authors:  B J Mayer
Journal:  J Cell Sci       Date:  2001-04       Impact factor: 5.285

8.  Nonenzymatic domains of Kalirin7 contribute to spine morphogenesis through interactions with phosphoinositides and Abl.

Authors:  Xin-Ming Ma; Megan B Miller; K S Vishwanatha; Maegan J Gross; Yanping Wang; Thomas Abbott; Tukiet T Lam; Richard E Mains; Betty A Eipper
Journal:  Mol Biol Cell       Date:  2014-03-05       Impact factor: 4.138

9.  The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability.

Authors:  Tarjinder Singh; James T R Walters; Mandy Johnstone; David Curtis; Jaana Suvisaari; Minna Torniainen; Elliott Rees; Conrad Iyegbe; Douglas Blackwood; Andrew M McIntosh; Georg Kirov; Daniel Geschwind; Robin M Murray; Marta Di Forti; Elvira Bramon; Michael Gandal; Christina M Hultman; Pamela Sklar; Aarno Palotie; Patrick F Sullivan; Michael C O'Donovan; Michael J Owen; Jeffrey C Barrett
Journal:  Nat Genet       Date:  2017-06-26       Impact factor: 38.330

10.  Opposite Modulation of RAC1 by Mutations in TRIO Is Associated with Distinct, Domain-Specific Neurodevelopmental Disorders.

Authors:  Sónia Barbosa; Stephanie Greville-Heygate; Maxime Bonnet; Annie Godwin; Christine Fagotto-Kaufmann; Andrey V Kajava; Damien Laouteouet; Rebecca Mawby; Htoo Aung Wai; Alexander J M Dingemans; Jayne Hehir-Kwa; Marjorlaine Willems; Yline Capri; Sarju G Mehta; Helen Cox; David Goudie; Fleur Vansenne; Peter Turnpenny; Marie Vincent; Benjamin Cogné; Gaëtan Lesca; Jozef Hertecant; Diana Rodriguez; Boris Keren; Lydie Burglen; Marion Gérard; Audrey Putoux; Vincent Cantagrel; Karine Siquier-Pernet; Marlene Rio; Siddharth Banka; Ajoy Sarkar; Marcie Steeves; Michael Parker; Emma Clement; Sébastien Moutton; Frédéric Tran Mau-Them; Amélie Piton; Bert B A de Vries; Matthew Guille; Anne Debant; Susanne Schmidt; Diana Baralle
Journal:  Am J Hum Genet       Date:  2020-02-27       Impact factor: 11.025

View more
  2 in total

Review 1.  Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia.

Authors:  Arne W Mould; Noura Al-Juffali; Annette von Delft; Paul E Brennan; Elizabeth M Tunbridge
Journal:  CNS Drugs       Date:  2021-12-20       Impact factor: 5.749

2.  Fish Hydrolysate Supplementation Prevents Stress-Induced Dysregulation of Hippocampal Proteins Relative to Mitochondrial Metabolism and the Neuronal Network in Mice.

Authors:  Julie Le Faouder; Bastien Arnaud; Régis Lavigne; Céline Lucas; Emmanuelle Com; Elodie Bouvret; Anne-Laure Dinel; Charles Pineau
Journal:  Foods       Date:  2022-05-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.